Comparison · NCT03355664-7945422d
Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 vs Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24: Polymerase Chain Reaction Corrected Efficacy Defined as Adequate Clinical and Parasitological Response (ACPR) by Study Arm
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 vs Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24: Polymerase Chain Reaction Corrected Efficacy Defined as Adequate Clinical and Parasitological Response (ACPR) by Study Arm. Trial comparisons, record NCT03355664-7945422d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03355664-7945422d
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.948 | 0.901 | 0.973 | wilson | |
| Risk in group 2 | 0.968 | 0.927 | 0.986 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0199 | -0.0705 | 0.0281 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.979 | 0.935 | 1.03 | log | |
| Odds ratio, group 1 over group 2 | 0.604 | 0.193 | 1.89 | log | |
Number needed to treat, for one fewer participant with the outcome on Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 than on Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 50.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | ACT: Artemether-lumefantrine (20/120 mg) as a fixed dose combination twice daily for 3 days according to weight plus low dose primaquine at hour 24 | 146 | 154 | OG000 |
| Group 2 | Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | TACT: Artemether-lumefantrine (20/120 mg) as a fixed dose combination twice daily for 3 days according to weight plus Amodiaquine (150mg) twice daily for 3 days according to weight plus low dose primaquine at hour 24 | 151 | 156 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Polymerase Chain Reaction Corrected Efficacy Defined as Adequate Clinical and Parasitological Response (ACPR) by Study Arm
- Description
- Efficacy is defined as participants, following initial parasite and fever clearance, not having a recrudescence of the original plasmodium infection and fever, up to 42 days of follow up.
- Time frame
- 42 days
- Population
Source ClinicalTrials.gov
Trial
- Title
- Study to Compare the Triple ACT AL+AQ With the ACT AL in Cambodia and Vietnam
- NCT number
- NCT03355664
- Phases
- PHASE3
- Conditions
- Malaria, Falciparum
- Interventions
- ACT, TACT
- Lead sponsor
- University of Oxford
- Results first posted
- 2022-07-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03355664?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03355664-7945422d